Atea Pharmaceuticals, Inc. Financing Cash Flow
Atea Pharmaceuticals, Inc. (AVIR) reported Financing Cash Flow of $257.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $257.00K.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $0.00.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$11.30M, a 9762.39% decline year-over-year.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$25.75M, a 9742.32% decline from fiscal 2024.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $267.00K, a 3.89% increase from fiscal 2023.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $257.00K, a 30.54% decline from fiscal 2022.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $370.00K, a 74.74% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $257.00K 10-Q · filed 2026-08-12 | $257.00K derived: sum of 3 quarters · filed 2026-08-12 | -$11.05M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $257.00K 10-Q · filed 2026-05-12 | $257.00K derived: sum of 2 quarters · filed 2026-05-12 | -$11.05M derived: sum of 3 quarters · filed 2026-05-12 | -$25.14M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$11.30M derived: sum of 2 quarters · filed 2026-03-05 | -$25.40M derived: sum of 3 quarters · filed 2026-08-12 | -$25.75M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$11.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$25.40M derived: sum of 2 quarters · filed 2026-08-12 | -$25.75M 10-Q · filed 2025-11-12 | -$25.75M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$14.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$14.44M 10-Q · filed 2026-08-12 | -$14.44M derived: sum of 3 quarters · filed 2026-08-12 | -$14.32M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$347.00K 10-Q · filed 2026-05-12 | -$347.00K derived: sum of 2 quarters · filed 2026-05-12 | -$230.00K derived: sum of 3 quarters · filed 2026-05-12 | -$230.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $117.00K derived: sum of 2 quarters · filed 2026-03-05 | $117.00K derived: sum of 3 quarters · filed 2026-03-05 | $267.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $117.00K derived: sum of 2 quarters · filed 2025-11-12 | $267.00K 10-Q · filed 2025-11-12 | $267.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $150.00K 10-Q · filed 2025-08-07 | $150.00K derived: sum of 3 quarters · filed 2025-08-07 | $242.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $150.00K 10-Q · filed 2025-05-12 | $150.00K derived: sum of 2 quarters · filed 2025-05-12 | $242.00K derived: sum of 3 quarters · filed 2025-05-12 | $242.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $92.00K derived: sum of 2 quarters · filed 2025-03-06 | $92.00K derived: sum of 3 quarters · filed 2025-03-06 | $257.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | $92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $92.00K derived: sum of 2 quarters · filed 2024-11-07 | $257.00K 10-Q · filed 2024-11-07 | $257.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $165.00K 10-Q · filed 2024-08-07 | $165.00K derived: sum of 3 quarters · filed 2024-08-07 | $312.00K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $165.00K 10-Q · filed 2024-05-14 | $165.00K derived: sum of 2 quarters · filed 2024-05-14 | $312.00K derived: sum of 3 quarters · filed 2024-05-14 | $312.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $147.00K derived: sum of 2 quarters · filed 2024-02-28 | $147.00K derived: sum of 3 quarters · filed 2024-02-28 | $370.00K 10-K · filed 2024-02-28 |
| 2022-09-30 | $147.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $147.00K derived: sum of 2 quarters · filed 2023-11-08 | $370.00K 10-Q · filed 2023-11-08 | $512.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $223.00K 10-Q · filed 2023-08-08 | $365.00K derived: sum of 3 quarters · filed 2023-08-08 | $1.16M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $223.00K 10-Q · filed 2023-05-08 | $365.00K derived: sum of 2 quarters · filed 2023-05-08 | $1.16M derived: sum of 3 quarters · filed 2023-05-08 | $1.22M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $937.00K derived: sum of 2 quarters · filed 2023-02-28 | $994.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.47M 10-K · filed 2023-02-28 |
| 2021-09-30 | $795.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $852.00K derived: sum of 2 quarters · filed 2022-11-07 | $1.32M 10-Q · filed 2022-11-07 | $427.54M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $528.00K 10-Q · filed 2022-08-08 | $426.75M derived: sum of 3 quarters · filed 2023-02-28 | $425.83M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $471.00K 10-Q · filed 2022-05-10 | $426.69M derived: sum of 2 quarters · filed 2023-02-28 | $425.78M derived: sum of 3 quarters · filed 2023-02-28 | $532.23M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $426.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $425.31M derived: sum of 2 quarters · filed 2023-02-28 | $531.75M derived: sum of 3 quarters · filed 2023-02-28 | $531.75M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$913.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $105.54M derived: sum of 2 quarters · filed 2021-11-12 | $105.53M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $106.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $106.44M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$6.00K 10-Q · filed 2021-05-13 | |||
| 2018-12-31 | $27.48M 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |